Clinical Research Directory

Inclusion Criteria: * Male or female, aged at least 18 years. * Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy, patients with relapsed/recurrent disease and prior treatment in early-stage setting allowed. * The tumour harbours an activating EGFR mutation * Enrolled in the AURORA registry * Patients must be either: * treatment-naïve for advanced NSCLC (allowing up to 2-cycles of bridging chemotherapy prior to molecular testing results) and initiated 1L Osimertinib per PBS restrictions from August 2020 to December 2022. * Previously treated with 1st or 2nd generation EGFR TKIs (gefitinib, erlotinib or afatinib) and confirmed T790M+ EGFRm at disease progression and initiated second-line Osimertinib per PBS restrictions from January 2016 to December 2022. Exclusion Criteria: There are no predefined exclusion criteria.